Navigation Links
Amylin Pharmaceuticals Reports 2007 Financial Results
Date:1/28/2008

ember 31, 2007, compared to $63.8 million for the same period in 2006.

Net loss was $76.9 million, or $0.57 per share, for the quarter ended December 31, 2007, compared to a net loss of $58.4 million, or $0.45 per share, for the same period in 2006.

Fourth quarter highlights

Highlights of Amylin's fourth quarter include the following:

-- Positive results from a 24-week study of monotherapy, or stand alone,

BYETTA in drug nave patients with type 2 diabetes. The Company plans

for a regulatory submission for a monotherapy indication to the U.S.

Food and Drug Administration, or FDA, in the first half of 2008.

-- Positive results from a 30-week comparator study of exenatide once

weekly injection and BYETTA taken twice daily in patients with type 2

diabetes. The Company anticipates a regulatory submission to the FDA by

the end of the first half of 2009.

-- Positive results from a 24-week proof-of-concept study with the

combination treatment of pramlintide, an analog of human amylin, and

metreleptin, an analog of human leptin in overweight or obese subjects,

validating the Company's novel integrated neurohormonal treatment of

obesity (INTO) strategy. The Company plans for additional clinical

development in 2008, including the initiation of a Phase 2B study.

Year ended December 31, 2007

Total revenue for the year ended December 31, 2007 was $781.0 million. This includes net product sales of $701.5 million, consisting of $636.0 million for BYETTA and $65.5 million for SYMLIN. This compares to total revenue of $510.9 million for the same period in 2006, including net product sales of $474.0 million consisting of $430.2 million for BYETTA and $43.8 million for SYMLIN.

Revenues under collaborative agreements were $79.5 million for the year ended December 31, 2007, compared to $36.8 million for the same period in 20
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
2. Amylin Pharmaceuticals to Present at Research & Development Day
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 2014 When head lice hits a home ... frenzy to get rid of it while keeping it from ... Gables now have the solution right in their neighborhood: ... Lice Troopers provides full spectrum head lice screening and treatment ... including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and ...
(Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
(Date:12/25/2014)... Each year trauma accounts for approximately 42 ... across the nation (according to the Centers for ... Hospital Ambulatory Medical Care Survey collected data from ... They estimated that there were between 3.5 and 4.4 ... diagnosis of broken bone or fracture. , When ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... 05, 2008 A new study published in Journal ... sclerosis (MS) patients to determine if the disease has affected ... progression of disability. , MS affects approximately 400,000 people in ... It is the most common cause of progressive disability in ...
... Professionals to Maintain Licensing or Certification, WASHINGTON, ... for completing an American Red Cross,First Aid/CPR Class ... happen., Red Cross has been approved as ... Association for Continuing Education and,Training (IACET). The approval ...
... survey shows people living with epilepsy often miss ... continues to build on the company,s commitment to ... XR(TM) (levetiracetam),extended-release tablets, -- Keppra XR(TM) is ... Epilepsy,Franchise, ATLANTA, Nov. 5 press release, ...
... havens for healing, but the numbers tell a different ... acquire after they,ve been admitted, and hospital-related infections continue ... heart disease. , Now, a radical new high-tech software ... these infections is now catching on faster than the ...
... for Medical Equipment, Facility,Design, Building Infrastructure and ... and NEW YORK, Nov. 5 Cirrus ... to provide a wide,range of technology and ... healthcare environments., (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Use Tobacco Settlement Money to Keep Kids from ... Executive Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. ... victory for the state,s kids and health by ... reduce smoking, save lives,and lower health care costs ...
Cached Medicine News:Health News:Multiple sclerosis progression can be predicted with MRI 2Health News:American Red Cross Offering Continuing Education Credits 2Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 2Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 3Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 4Health News:Keppra XR(TM) Offers Convenient Dosing For People With Partial Onset Seizures 5Health News:Reducing epic proportions 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 2Health News:Cirrus Health and Siemens Announce Technology Alliance to Deliver the Physician-Driven Hospital of the Future 3Health News:North Dakota Votes to Keep Promise to Kids by Fully Funding Tobacco Prevention 2
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... 2012  Coloplast North America today announced that a federal ... Devices, Inc. (GMD) was infringing on a Coloplast Urology ... stress urinary incontinence in women. Using this approach, surgeons ... regain control of their bladder. The jury ...
... Systems (NASDAQ: DCTH ) today announced financial results ... 2012 and recent weeks.  Highlights for the ... of CE Mark approval for the second generation hemofiltration cartridge ... , Treatment of the first patient with Generation 2 ...
Cached Medicine Technology:Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc. 2Delcath Highlights First Quarter 2012 And Recent Accomplishments 2Delcath Highlights First Quarter 2012 And Recent Accomplishments 3Delcath Highlights First Quarter 2012 And Recent Accomplishments 4Delcath Highlights First Quarter 2012 And Recent Accomplishments 5Delcath Highlights First Quarter 2012 And Recent Accomplishments 6Delcath Highlights First Quarter 2012 And Recent Accomplishments 7
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: